RB ended the year at the opposite end of the spectrum from where it started, reporting a disappointing top-line performance for the full year (its worst in the last decade), with FY 16 lfl sales growth missing its own guidance (3% vs. 4% expected) as well as the street’s expectations. On a quarterly basis, Q4 16 capped the unusually soft year, which saw the company record its fourth straight quarter of organic growth decline (+1% in Q4 from Q3: 2%, Q2: 5% and Q1: 10%) with Health contra
28 Mar 2017
RB resorting to new ‘formula’ to revive growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RB resorting to new ‘formula’ to revive growth
Reckitt Benckiser Group plc (RKT:LON) | 4,521 0 0.0% | Mkt Cap: 32,030m
- Published:
28 Mar 2017 -
Author:
Jyoti Prakash -
Pages:
4
RB ended the year at the opposite end of the spectrum from where it started, reporting a disappointing top-line performance for the full year (its worst in the last decade), with FY 16 lfl sales growth missing its own guidance (3% vs. 4% expected) as well as the street’s expectations. On a quarterly basis, Q4 16 capped the unusually soft year, which saw the company record its fourth straight quarter of organic growth decline (+1% in Q4 from Q3: 2%, Q2: 5% and Q1: 10%) with Health contra